Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.

MLA

Liao, David S., et al. “Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.” Ophthalmology, vol. 127, no. 2, Feb. 2020, pp. 186–95. EBSCOhost, https://doi.org/10.1016/j.ophtha.2019.07.011.

APA

Liao, D. S., Grossi, F. V., El Mehdi, D., Gerber, M. R., Brown, D. M., Heier, J. S., Wykoff, C. C., Singerman, L. J., Abraham, P., Grassmann, F., Nuernberg, P., Weber, B. H. F., Deschatelets, P., Kim, R. Y., Chung, C. Y., Ribeiro, R. M., Hamdani, M., Rosenfeld, P. J., Boyer, D. S., & Slakter, J. S. (2020). Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology, 127(2), 186–195. https://doi.org/10.1016/j.ophtha.2019.07.011

Chicago

Liao, David S., Federico V. Grossi, Delphine El Mehdi, Monica R. Gerber, David M. Brown, Jeffrey S. Heier, Charles C. Wykoff, et al. 2020. “Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.” Ophthalmology 127 (2): 186–95. doi:10.1016/j.ophtha.2019.07.011.